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Abstract
Mechlorethamine (HN2), a nitrogen derivative of mustard gas, was the first synthetic
anti-tumor chemotherapeutic because it forms covalent cross-links between strands of duplex
DNA. HN2 represents a class of bifunctional alkylating agents that are both chemotherapeutic
and carcinogenic: diepoxybutane (DEB), the active form of the pro-drug treosulfan, and
epichlorohydrin (ECH), a structural hybrid of HN2 and DEB, also form covalent cross-links
between DNA. While HN2 and DEB are clinically used as anti-tumor chemotherapeutics, ECH
is a structural hybrid of these two compounds not used in a clinical setting. Accordingly, we
aimed to understand the relationship between the cross-linking potential of these compounds and
their ability to induce cell death (apoptosis). Cytotoxicity rankings were determined by assessing
the median lethal dose (LD50) concentrations using MTT Cell Proliferation Assays for 12- and
24-h treatments (HN2 >> DEB > ECH; DEB > HN2 > ECH, respectively). Cross-linking
potentials at equimolar concentrations suggest DEB > ECH > HN2 for a 24-h treatment. Finally,
these compounds’ abilities to induce apoptosis at 12- and 24-h equitoxic concentrations were
assayed over 12- and 24-h treatments, suggesting that DEB >> ECH > HN2. Accordingly, we
propose a relationship between a compound’s ability to form cross-links and the induction of cell
death and apoptosis (DEB > ECH > HN2) when considering reactivity and stability of unreacted
cross-linkers over time. Future studies will aim to elucidate the cross-linking potential at
equitoxic concentrations for each of these three compounds over multiple time frames.
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Introduction
DNA Alkylating Agents: Importance, Mechanism, and Cross-Linking
The cytotoxic effects of mustard gas were realized during World War I in its deployment
as a chemical weapon against Allied forces. Autopsies of exposed soldiers revealed its ability to
severely deplete bone marrow, raising the possibility for its use as an anti-tumor agent to treat
Hodgkin’s leukemia [1]. The water-soluble nitrogen derivative, mechlorethamine hydrochloride
(HN2, Table 1) was later used as a chemotherapeutic in patients with leukemia and shown to
decrease tumor size and delay death [2]. HN2 ultimately revolutionized the war on cancer as it
became the first synthetic anti-tumor chemotherapeutic used clinically, suggesting the possible
use of bifunctional alkylating agents as anti-tumor chemotherapeutics [1,3].
Bifunctional

alkylating

agents are compounds that use two

Table 1. Bifunctional alkylating agents used in this study.
Name
Abbreviation
Structure
CH3
Mechlorethamine
HN2

functional groups (e.g. chloride or

N
Cl

epoxide) to alkylate and form

1,2,3,4Diepoxybutane

DEB

covalent, interstrand cross-links in

(±)-Epichlorohydrin

ECH

Cl

O

O

O

Cl

duplex DNA. These cross-links
prevent double stranded DNA (dsDNA) from separating, making transcription and replication
nearly impossible without specific repair enzymes. Accordingly, the formation of these crosslinks is believed to be the source of the cytotoxicity of HN2 and other bifunctional alkylating
agents [4].
The ability of HN2 to induce DNA damage has been harnessed in the drug Mustargen®,
which is currently used topically to treat melanomas. These cross-links are primarily formed
between the N7 sites of distal guanosine residues in the sequence 5!-GNC [4]. Unfortunately, in
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addition to stopping cell proliferation, HN2 has the potential to cause insertions, rearrangements,
and point mutations within the DNA of cancerous and healthy cells alike [5]. As a result,
treatment has the potential to lead to an increased risk of developing secondary cancers [6,7].
Another bifunctional alkylating agent used to treat cancer is 1,2,3,4-diepoxybutane (DEB,
Table 1). DEB is believed to be the active form of the anti-tumor pro-drug treosulfan (Ovastat),
which has been used to treat advanced ovarian cancers [8,9]. Cross-linking DNA similarly to
HN2 [10], DEB exerts cytotoxic effects that are also non-specific to cancer cells. DEB’s
carcinogenicity has been observed in mice and rats [11,12], as well as in humans [13]. A link
between industrial workers exposed to 1,3-butadiene (BD), the metabolic precursor to DEB, and
a high occurrence of leukemia has been documented [14-18], raising concerns about its dual
chemotherapeutic and carcinogenic nature. Its ubiquitous presence in gasoline, automobile
exhaust, and cigarette smoke (~20-75 µg/cigarette) are enough to cause cross-linking and induce
apoptosis [19], making its exposure to civilian populations especially alarming. A cause for
further concern is the approximately four million pounds of BD released from the production of
synthetic rubber, polymers, and plastics from US facilities each year [20]. This staggering figure
highlights the need to study DEB and its ability to cross-link and induce cell death [21,22] more
in depth.
While not currently used as an anti-tumor chemotherapeutic, epichlorohydrin (ECH,
Table 1) is a structural hybrid of HN2 and DEB. ECH has also been identified as a suspected
mutagen and probable carcinogen [23]. In 2003, approximately 203,900 metric tons of ECH
were used in the production of synthetic polymers, epoxy resins, glycerine, and elastomers [24].
ECH forms cross-links similar to HN2 and is also capable of reacting with free bases at the N6
and N3 of adenine and O6 on guanine [25-29]. It has been hypothesized that the 3-atom cross-link
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formed by ECH would be too small to cross-link duplex DNA [30]; however, in vitro studies
performed by our lab [31] and in vivo studies on mammalian cell cultures counter this hypothesis
[32-35]. Further, in mammalian cell cultures, ECH has been shown to be mutagenic [36],
clastogenic [37], and able to induce neoplastic cell transformations [23], papillomas, and
carcinomas [38]. Due to cross-link formation, chromosomal aberrations, and cell damage, the
risk of developing cancer greatly increases upon exposure to ECH [23,24,39,40]. Each year, an
estimated 250,000 industrial workers in the United States will contact ECH, potentially raising
their risk of cancer. Therefore, understanding ECH’s cross-linking potential and cytotoxicity are
important for furthering our understanding of this compound’s health risks.

Characterizing the relationship between cross-linking and cytotoxicity for these compounds
The purpose of this study is to understand the abilities of the three compounds (HN2,
DEB and ECH) to form interstrand cross-links within double stranded DNA in vivo and how the
formation of cross-links relates to cytotoxicity and the induction of apoptosis (Figure 1). We
determined the median lethal dose (LD50) as a measure of cytotoxicity after 12- and 24-h
treatments using the MTT Cell Proliferation assay. The potential for each compound to form
interstrand cross-links at equimolar concentrations over 24-h was investigated using an ethidium
bromide fluorescence assay. Finally, the apoptotic potential of these compounds was determined
by the detection of two hallmark apoptotic proteins, active caspases 3 and 7, using a CaspaseGlo® 3/7 assay. Accordingly, these three tests suggest a relationship between the ability of these
compounds to form cross-links and their abilities to induce cell death and trigger an apoptotic
response.
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Formation of covalent
interstrand cross-links
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O
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Epichlorohydrin (ECH)
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N
Cl

Cl

Mechlorethamine (HN2)

Cross-Linking

Apoptotic Window

Cytotoxicity
Healthy vs. Apoptotic Cells
Figure 1. Schematic of overview this study. HL-60 cells were treated with DEB, ECH, and HN2 for 12- or 24-h.
Cross-linking potentials were determined using an ethidium bromide fluorescence assay, which was compared to the
cytotoxicity as measured through the MTT Cell Proliferation Assay and compounds’ ability to trigger an apoptotic
response as detected by the Caspase-Glo® 3/7 assay.
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Materials And Methods
Cell Lines and Cell Culture
Human acute myeloid leukemia (HL-60) cells (American Type Culture Collection) were
cultured in RPMI 1640 (Lonza) containing 10% fetal bovine serum (FBS; Carolina Biologicals)
and broad spectrum antibiotics (10,000 I.U./mL Pennicillin and 10,000 µg/mL Streptomycin;
Cellgrow) at 37oC, in 5% CO2. Stocks were maintained at approximately 3.0 - 4.0 x 105 cells/mL.
Stock viability and density were measured using 2.0 µL Trypan Blue 0.4% stain (Lonza) and
20.0 µL cell suspension. After brief mixing, 20 µL were injected into SD100 Cellometer cell
counting chambers and counted using a Cellometer T4 Nexelcom, automated haemocytometer
with the accompanying Cellometer Auto T4 Software. The concentration and viability of each
stock were determined using the HL-60 cell type setting.
Drug Treatments
Stocks of each bifunctional alkylating agent (1.0 M) were prepared for each trial in either
DMSO (DEB and ECH) or 0.1 N HCl (HN2). Treatments were administered such that wells
contained 1% v/v alkylating agent in vehicle solution. Cells were aliquoted into 6-well plates to
maximize surface area exposure at a concentration of 3.0-4.0 x 105 cells/mL. Cells were treated
continuously in growth media containing various concentrations of a bifunctional alkylating
agent and assayed after 12 or 24 hours. Treated cells were compared relative to a number of
controls: negative controls containing cell-free RPMI 1640 media, and a vehicle control with
either 1% v/v DMSO or 0.001 N HCl. For the Caspase-Glo 3/7® assay, a positive control of 0.15
µM camptothecin (DNA topoisomerase I inhibitor) in DMSO was prepared and administered 2.5
hours prior to each treatment interval [41-43].
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MTT Cell Proliferation Assay
A Cell Quanti-MTT Cell Proliferation Assay (BioAssay Systems) was used for a precise
determination of equitoxic (LD50) concentrations over 12- and 24-h treatments. The MTT Cell
Proliferation Assay uses the reduction of yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)2, 5-diphenyltetrazolium bromide) by succinate dehydrogenase in metabolically active cells to
create MTT formazan, a purple precipitate that can be used to spectrophotometrically quantitate
metabolically active cell populations [44].
Cells were treated at an initial density of 3.0 – 4.0 x 105 cells/mL. After the appropriate
incubation interval, triplicates of 18.75 µL reconstituted MTT reagent were added to 100 µL
aliquots of treated and untreated cells into a clear bottom, 96-well plate. After a 4 hour
incubation at 37oC and 5% CO2, cells were lysed with 125 µL solubilization buffer and shaken at
120 RPM until the purple precipitate homogenized within the well (3-10 hours). Absorbances of
the purple precipitate (570 nm) were measured using a SPECTRAmax M2 plate reader and
SoftMax® Pro Software (Molecular Devices).
MTT Cell Proliferation LD50 Data Analysis
Absorbance values were electronically transferred to Microsoft Excel 2011. Using a
technique described previously by former Millard labmate Christopher Ng, I solved for the
viable fraction (VF) of cells by taking the fraction of the blanked (RPMI media) average of an
individual treatment divided by the blanked average of the positive control (0.15 µM
camptothecin in DMSO), Equation 1. The fit viable fraction [P(c)] was calculated using Equation
2, where “c” is concentration, parameter “a” is the LD50 concentration (mM), and parameter “b”
is a scaling exponent. The residual sum of squares for a non-linear data set [=SUMXMY2(viable
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fraction, fit viable fraction)] was used to determine the quality of fit between the two values in
Excel. Using the Solver add-in for Excel, the residual sum of squares was minimized by
changing the parameters (a > 0, b > 0). Only one parameter could be minimized for each set of
100 iterations through Excel, so each parameter was changed until the “a” parameter stayed
constant up to the fourth significant digit. For each parameter and the residual sum of squares,
an uncertainty value was calculated using a non-linear least squares macro, SolverAid, from
Robert de Levi’s MacroBundle12 [45]. This macro “provides uncertainty estimates (standard
deviations and the covariance matrix) for Solver-derived parameter values.” Accordingly, we
were able to calculate the LD50 value and its uncertainty for each compound at each time interval.
VF = (Sample A570 – Mean Blank A570)/(Mean Control A570 – Mean Blank A570)
P(c) = 1/(1+(c/a)b)

(1)
(2)

Ethidium Bromide Fluorescence Assay
An ethidium bromide fluorescence assay [13] was used to assess the degree of crosslinking for each compound at an equimolar concentration (1.0 µM) over a 24-h treatment (Figure
1). Ethidium bromide is an intercalating agent that binds DNA, fluorescing more when bound to
duplex DNA than single stranded DNA (ssDNA). This property can be used to assess the ability
of our test compounds to cross-link duplex DNA. By measuring fluorescence before and after a
rapid denature-renaturation cycle, we could determine how easily the DNA was able to reanneal.
A greater abundance of cross-links will aid in the renaturing of complementary strands of DNA
to their initial conformation, thereby increasing the proportion of duplex DNA to ssDNA. In
other words, strands that can realign more completely will have more bases that match,
permitting greater fluorescence of the ethidium bromide during a second fluorescence reading.
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Genomic DNA was extracted from unsynchronized HL-60 cells using a GenCatch
Genomic DNA Extraction Kit following the Blood protocol (Qiagen). The concentration of each
DNA sample and the ratio of DNA:protein (A260/280) was measured using a Nanodrop-1000
Spectrophotometer. Samples were eluted in Tris-EDTA (TE) buffer (pH 9.0) and diluted with TE
to 20 ng DNA/µL. 100 µL of extracted genomic DNA and 100 µL ethidium bromide (10 µg/mL)
solution containing 20 mM K2HPO4 and 0.4 mM EDTA (pH 12.0) were aliquoted into a flatbottom, black 96-well plate.
Baseline fluorescence readings (RFU) were recorded for each well prior to a rapid
denature-renaturation cycle. This cycle consisted of a 5-minute incubation at 100oC, then 3
minutes in a -20oC freezer. A spectrum sweep for emission and excitation wavelength maxima
was determined to be 525 nm for excitation and 580 nm for emission, matching literature values.
!

Extract DNA from
treated cells and
stain with ethidium
bromide

Measure baseline
fluorescence

Rapid strand
separation-rejoining

(High fluorescence)

Measure final
fluorescence

Relative % Cross-Linking = (EA/EB) – (CA/CB)
1 — (CA/CB)
EA = Experimental fluorescence after denaturation
EB = Experimental fluorescence before denaturation
CA = Untreated fluorescence after denaturation
CB = Untreated fluorescence before denaturation

Cross-linked
or

(Higher fluorescence)

Not cross-linked
(Lower fluorescence)

Figure 2. Schematic for ethidium bromide cross-linking assay. Ethidium bromide was excited at 525 nm and
fluorescence values were measured at 580 nm.
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Fluorescence readings were recorded before and after this heat-chill cycle. The relative
percent of cross-linking was calculated using the equation for relative percent cross-linking in
Figure 2 [13,44]. By taking the difference between the ratio of experimental to control
fluorescences, and dividing that by a theoretically, fully cross-linked sample, we were able to
calculate the cross-linking potential of each alkylating agent.

Caspase-Glo® 3/7 Assay
A Caspase-Glo-3/7 assay was used to determine relative levels of apoptosis based on the
detection of caspases 3 and 7. This assay uses a proluminescent caspase-3/7 DEVDaminoluciferin substrate with a proprietary thermostable luciferase to generate a luminescent
signal as active caspases 3 and 7 cleave the aminoluciferin from the substrate. Luciferase cleaves
the aminoluciferin to create a luminescent signal that is proportional to the abundance of these
active caspases, thus quantitating the apoptotic response.
Twelve and 24-h treatments with each cross-linker at both 12- and 24-h LD50
concentrations were compared with the positive control for apoptosis (0.15 µM camptothecin in
1% v/v DMSO). Using a 1:1 ratio of caspase reagent to treated cells, treated cells and
reconstituted caspase reagent were aliquot onto an opaque white, round-bottom 96-well plate.
The plate was mixed at 200 RPM for 30 seconds, then left to incubate for 30 minutes at 37oC and
5% CO2.
Relative luminescent units (RLU) were measured using a SPECTRAmax M2 plate reader
and SoftMax® Pro Software (Molecular Devices). The mean luminescent signal of each
condition was blanked with the mean negative control (RPMI 1640-based cell-free media).
Relative levels of apoptosis were determined by taking the fraction of the blanked-adjusted
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average of an individual treatment divided by the blanked-adjusted average of the positive
control. Vehicle controls of 1% v/v DMSO and/or 1% v/v 0.1 N HCl were also assayed.
Standard error mean (S.E.M; bars displayed in Figure 1) were calculated by dividing the
standard deviation by the square root of the sample size. Significance between treatment and
vehicle controls were determined using a student’s t-test for statistical analysis of the variance
between two means.
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Results
Cytotoxic Potential
Cells react differently to bifunctional alkylating agents based on their position in the cell
cycle [41], cell line and type, length of treatment (time), and dosing concentration [46].
Unsynchronized HL-60 cells were treated with varying concentrations of bifunctional alkylating
agents. Based on the concentration-dependent response, we were able to establish the median
lethal dose (LD50) for each treatment condition.
The

cytotoxicity

of

each

compound is inversely proportional to
its

LD50

X-Linker

12 Hour

24 Hour

HN2

0.000410 ± 0.0000552

0.0217 ± 0.00263

more

potent

DEB

a

lower

0.226 ± 0.0110

0.0174 ± 0.00085

ECH

0.492 ± 0.0354

0.175 ± 0.0163

concentration to eliminate half the

12-h

HN2 >> DEB > ECH

24-h

DEB > HN2 > ECH

compounds

value;

Table 2. LD50 values and ± S.E.M. (mM) for HL-60 cells treated
with bifunctional alkylating agents over 12- and 24-h periods.
Subscripts indicate uncertainty of the uncertainty value, n = 3.

require

fraction of viable cells. In the case of

HN2, the LD50 concentration at 12-hours was approximately 550-fold less than DEB and
approximately 2,000-fold less than ECH, indicating a potency ranking of HN2 >> DEB > ECH
(Table 2). After 24-hours, the LD50 of DEB was markedly lower than HN2 and approximately
10-12 fold greater than ECH (DEB > HN2 > ECH; Table 2).
Of note, the LD50 values for DEB and ECH decreased (13.0 and 2.8-fold, respectively)
between the 12- and 24-h treatments, suggesting that they become slightly more toxic over time.
However, the LD50 value for HN2 increased 50-fold over the same time interval, suggesting that
cytotoxicity, or number of metabolically active cells, decreases over time.
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Cross-Linking Potential
It has been proposed previously that a bifunctional alkylating agent’s ability to cross-link
DNA is the cause of its cytotoxicity [47]. The ethidium bromide fluorescence assay was used to
understand how well each compound is able to form cross-links with DNA. Genomic DNA was
extracted from unsynchronized treated and untreated cells then stained with ethidium bromide.
Because ethidium bromide fluoresces when bound to dsDNA versus ssDNA, comparison of
fluorescences before and after a rapid denaturation-renaturation cycle could be used to estimate
the relative number of cross-links in a given condition when compared to an untreated control.
Due to time constraints and complications in the protocol, we were only able to obtain
data for 24-h treatments with 1.0 µM of each cross-linker. DEB (37.1%) was the most potent
cross-linker followed by ECH (14.0%), then HN2 (2.6%), suggesting a cross-linking order of
DEB > ECH > HN2. While this does not characterize the compounds at equitoxic (LD50)

Relative Percent Cross-Linking

45.00
40.00
35.00
30.00
25.00
20.00
15.00
10.00
5.00
0.00
-5.00

HN2

ECH

DEB

Cross-linker
Figure 3. Ethidium bromide fluorescence assay for a 24-h treatment with 1.0 µM of each compound indicates the
cross-linking strengths: DEB > ECH > HN2. The formation of covalent, interstrand cross-links prevents DNA from
separating, allowing it to reanneal easier and fluoresce more after a rapid denature-renaturation cycle, n = 3.
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concentrations, it allows us to speculate these compounds’ abilities to enter the cell and react
with the DNA over a longer treatment length.

Apoptotic Potential
Apoptotic potentials for each compound were assayed across four conditions where the
treatment time (12- and 24-h) and LD50 concentration at each time were varied (Figure 4).
Compared against vehicle controls, cells treated with DEB showed significant levels of apoptosis
induced for three test conditions: both 12- and 24-h LD50 concentrations (0.226 mM and 0.0174
mM) during a 24-h treatment (p < 0.00001 and p < 0.00001) and during a 12-h treatment with
the 24-h LD50 (p < 0.00001). Treatment at these three conditions caused levels of apoptosis that
differed significantly from each other: 24-h LD50 treated for 24-h > 12-h LD50 treated for 12-h >
24-h LD50 treated for 12-h (p < 0.00005 for each combination).
Treatment with ECH caused significant levels of apoptosis for two test conditions: 24-h
LD50 for the 12- and 24-h treatments (0.175 mM; p < 0.05 and p < 0.01), when compared against
the vehicle control. Each treatment differed significantly from the other as well, with the 24-h
treatment inducing a greater apoptotic response than the 12-h treatment (p < 0.0005).
Treatment with HN2, using the 12-h LD50 concentration (0.000410 mM) over a 24-h
interval, induced significant levels of apoptosis (p < 0.005) when compared against its vehicle
control. However, the magnitude of this apoptotic response was very low.
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Lminescence Fraction

a

1.0

!!"

0.9
0.8
0.7
0.6
0.5
0.4

!"

0.3
0.2

!"

0.1
0.0

12 hour treatment

Untreated

Vehicle
(0.1 N HCl)

HN2
0.000410 mM

HN2
0.0217 mM

Vehicle
(1.0% DMSO)

ECH
0.492 mM

ECH
0.175 mM

DEB
0.226 mM

DEB
0.0174 mM

0.093

0.089

0.091

0.086

0.185

0.190

0.220

0.208

0.825

1.0

Lminescence Fraction

b

!!"

0.9
0.8
0.7

!!"

0.6
0.5
0.4

!"

0.3
0.2
0.1
0.0

24 Hour Treatment

Untreated

Vehicle
(0.1 N HCl)

HN2
0.000410 mM

HN2
0.0217 mM

Vehicle
(1.0% DMSO)

ECH
0.492 mM

ECH
0.175 mM

DEB
0.226 mM

DEB
0.0174 mM

0.078

0.090

0.115

0.080

0.241

0.248

0.286

0.583

0.924

Figure 4. Relative levels of apoptosis induced by LD50 concentrations of bifunctional alkylating agents after (a) 12 and (b) and
24-hour treatments. Significant levels of apoptosis were induced for three treatments with DEB, two with ECH, and one with
HN2. Asterisks indicate significance (* = p < 0.005, ** = p < 0.00001) between luminescence fractions of treatment conditions
and their respective vehicle controls, n = 3.
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Discussion
The ability for our test compounds to enter cells and form interstrand cross-links is
believed to be the source of their cytotoxicity. These compounds are highly reactive within the
cells, though we focused specifically on their ability to interact with genomic DNA. Accordingly,
we sought to characterize their cytotoxicity, specifically their ability to induce apoptosis, at
equitoxic (LD50) concentrations with respect to their ability to form these interstrand cross-links.
Cytotoxicity of Bifunctional Alkylating Agents
Equitoxic concentrations of unsynchronized HL-60 cells were determined based on the
median lethal dose determined using the MTT assay. During the 12-h treatment, HN2 was
markedly more cytotoxic than either DEB (550-fold) or ECH (2,000-fold); however, DEB was
more cytotoxic than HN2 during the 24-h treatment and only slightly more so than ECH.
The increase in LD50 concentration for HN2 was surprising. Higher levels of metabolism
were detected from cells treated with HN2 over a 24-h treatment than would be theoretically
possible considering the 12-h LD50 concentration and the 24-36 hour doubling time of HL-60
cells. It is important to recognize that the MTT assay measures the metabolic activity; it does not
directly quantitate cell death. Cells that contain cross-linked DNA may be less metabolically
active than healthy cells, but they necessarily dead. This discrepancy is noteworthy, since the
LD50 concentration for HN2 increased 50-fold over the twelve hours between assaying for
cytotoxicity, while the LD50 for ECH and DEB decreased (~3 and 12-fold, respectively). This
trend may be due, in part, to the stability of these compounds once in aqueous solution. HN2 is
reported to have a very short half-life in aqueous solution, dependent upon the nature of the
reactant [48] and the medium in which it is solvated [49]. A theoretical minimum half-life based
on the time it takes HN2 to cyclize into the ethylene imonium ion, the reactive species in HN2’s
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nucleophilic reactions, is approximately 90 seconds [50]. One source suggests 0.2 mM HN2 has
a half-life of approximately 30 minutes [50]. In comparison, DEB and ECH have reported halflives of 31 ± 4 [51] and 213 [29] hours, respectively. The substantially longer half-life of these
compounds may increase their potency over prolonged treatment lengths and slow down the rate
of replication. Cells exposed to a compound that breaks down quickly will be exposed to it for
less time, allowing them a chance to repair cross-links using DNA excision repair enzymes. This
can allow for more potent and targeted treatments while decreasing the chance of collateral
damage to neighboring healthy tissues. However, the ability for treated cells to recover quickly
after treatment raises the chances of developing secondary or more resilient cancers [52].

Cross-Linking at Equimolar Concentrations Suggests DEB > ECH > HN2
The cross-linking ability of these compounds was measured using the ethidium bromide
fluorescence assay using 1.0 µM of each compound over a 24-h treatment. Data from the
ethidium bromide fluorescence assay indicate a positive correlation between cross-links formed
and trends in cytotoxicity from DEB and ECH in the context of compound half-life. These crosslinking results indicate DEB > ECH > HN2. These results differ from earlier in vitro studies
conducted within the Millard lab, which suggest HN2 is a more potent cross-linker than DEB
[53], and that DEB is a more potent cross-linker than ECH [31].
The potency of these cross-linkers in vitro is similar for to their cytotoxicity determined
for the 12-h treatment, but not 24-h treatment. This discrepancy is likely due to the compounds’
half-lives. Despite ECH’s longer half-life, its ability to form cross-links is much less than both
DEB and HN2. Therefore, its more concentrated presence in solution over a 24-h is not enough
to induce more cross-links than DEB.
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While HN2 is the most reactive cross-linker in vitro, it is not necessarily the best crosslinker. HN2’s ability to form cross-links in vitro is less biologically relevant than its half-life
when used to treat live cells. Since its half-life is so short, cross-links will only form for a certain
period of time before the compound’s presence in solution in negligible. The rate of cross-link
repair in cells will eventually overcome that of the decreasing rate of cross-link formation. This
hypothesis may also help explain why the potency of HN2 decreases over time, while the
potency of the epoxides increases. The instability of HN2 over longer periods of time may also
help to explain why our in vivo cross-linking results (DEB > ECH > HN2) differ from our in
vitro results (HN2 > DEB > ECH).
Another possible reason for the disparity between HN2’s in vivo and vitro cross-linking
potentials are the compounds’ ability to permeate the cells and interact with the DNA. Previous
studies solvated DEB and ECH in DMSO and HN2 in an acidic aqueous solution. The difference
in solvent may ultimately affect the permeability of these compounds into the cell and nucleus,
which could affect our results and explain the increased cross-linking observed with DEB and
ECH. However, due to time constraints and complications with the ethidium bromide crosslinking protocol, we were unable to test this hypothesis and establish data for equitoxic
concentrations over the different time points. These aspects of bifunctional alkylating agent
biochemistry may be biologically relevant aspects to consider further.

High Apoptotic Potential of DEB
The induction of apoptosis is important in treating tumors and cancers for two reasons.
First, the increased replication rate of a cancer cell means that damage caused that may interrupt
cellular replication will slow or stop the rate of proliferation, which provides the immune system
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an opportunity to destroy the cancerous cells. Second, triggering apoptosis is a more targeted
approach to chemotherapy. Cells with damage induced by chemotherapeutics will be stopped at
one of the checkpoints in replication, which can mean it is more likely to trigger an apoptotic
response if it is stopped for too long. Therefore, cells that replicate abnormally fast are more
likely to be selected against than cells that undergo fewer replications in a given timeframe. In
contrast, necrosis is a form of cell death that causes unregulated cell death and can affect both
healthy and cancerous cells.
A cell’s ability to undergo apoptosis is largely dependent on its type, length and
concentration of treatment, and its progression through the cell cycle [46]. Previous studies
suggest that DEB is capable of triggering apoptosis [54-58], ECH has an overwhelming ability to
induce necrosis [59], and HN2 is able to stimulate both necrosis and apoptosis [48], depending
on an apoptotic window, as determined by the treatment concentration (lower concentrations
induce apoptosis) and length (shorter treatments of 1-h induce apoptosis) [60]. By assaying for
the activity of active caspases 3 and 7, two hallmark proteases of apoptosis, we were able to
determine how well these compounds induced apoptosis at specified equitoxic concentrations.
Thus, we demonstrated that while there is no direct correlation between cross-linking and
compound-induced cytotoxicity (apoptosis), a relationship might exist if the stability of
unreacted cross-linkers is taken into account.
DEB showed the most significant levels of apoptosis over both 12- and 24-hour
treatments and the greatest number of conditions in which apoptosis was induced (Figure 4).
With the exception of the 12-h LD50 during a 12-h treatment, DEB showed very significant
levels of apoptosis (24-h LD50 after 24-h treatment > 24-h LD50 after 12-h treatment > 12-h LD50
after 24-h treatment > 12-h LD50 after 12-h treatment = vehicle control). DEB is largely believed
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to be the active form of the pro-drug treosulfan, which is used to treat advanced stages of ovarian
cancer. Studies on treosulfan in human acute myeloid leukemia cells, including HL-60, indicate
that the physical biological features associated with apoptosis (e.g. membrane blebbing) are
clearly present in cells treated with treosulfan after 72 hours, further highlighting the ability of
DEB to induce apoptosis [56]. It is likely that we observed apoptosis prior to this time point
because DEB is the pro-form of treosulfan. In order for treosulfan to become active and form
cross-links as DEB, it must be broken down. On the contrary, since DEB is already the active
form and can react immediately it should be able to begin forming cross-links sooner.
Cells treated with the lower, 24-h ECH LD50 concentration induced apoptosis over both
time intervals. While this challenges the primarily necrotic response reported in previous studies
[59], it does support previous work that lower concentrations of bifunctional alkylating agents
can induce apoptosis [60]. Finally, cells treated with the 12-h LD50 concentration of HN2 for 12h also induced statistically significant levels of apoptosis when compared to the vehicle control.
However, these levels of apoptosis were very small and may have little biological relevance.

DEB Shows Strong Relationship between Cross-Linking and Cytotoxicity/Apoptotic Response
The half-life of a compound must be known to understand how long cross-linking can
occur after a cell’s initial exposure. Therefore, we propose a relationship between cross-linking
and cytotoxicity (induction of apoptosis) for the three test bifunctional alkylating agents over
longer treatment lengths.
DEB and ECH each have half-lives that are greater than the length of treatment. Of the
initial treatment concentration over 12- and 24-h, DEB (76.5% and 58.5%) and ECH (96.2% and
92.5%) were still largely present in the treatment wells. For these same time intervals, HN2 (6.0
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x 10-6 % and 3.6 x 10-13 %) decayed and had a negligible presence in the treatment wells. Cells
exposed to DEB and ECH were able to continue to form cross-links with genomic DNA long
after HN2 was broken down and HN2-exposed cells had begun to repair these cross-links.
Therefore, while HN2 may be more cytotoxic in shorter doses, DEB and ECH have a prolonged
effect that contributes to their ability to form cross-links, ultimately inducing cell death and
apoptosis. This property of the epoxides may cause collateral damage in neighboring tissues,
representing a clear disadvantage to treatment with such compounds.
Of all three of the test compounds, DEB showed the strongest support for the hypothesis
that cross-linking potential is correlated with the induction of apoptosis. Results from ECH also
support this hypothesis, since cross-links form over a 24-h period and low, yet significant, levels
of apoptosis were induced. Finally, despite HN2’s high potency during shorter treatments, it was
unable to continually cross-link DNA, likely a result of a theoretically lower presence after a
certain period of time. HN2’s degradation provides a window of opportunity for the
metabolically viable cells to repair cross-linking and continue to divide after treatment. It is
possible that HN2’s cross-linking and apoptotic potentials may be much greater than DEB’s if
assays were performed much closer to the time of treatment when a substantial concentration of
reactive HN2 was present. However, the short half-life of HN2 limits the window of exposure,
which may be an advantage relative to other compounds when it comes to reducing collateral
damage in healthy cells nearby but disadvantage because selection favors resiliency to treatment.

!

##!

Conclusion
In this study, we suggest that a bifunctional alkylating agent’s potential to cross-link
duplex DNA and to induce cell death by triggering apoptosis are related when considering a
compound’s stability in solution. The cross-linking potential of these three compounds at
equimolar concentrations suggests that DEB was the most effective, followed by ECH, then HN2.
The ability of these compounds to cross-link was largely dependent on their ability to permeate
the cell and bind DNA, as well as their stability in solution. Therefore, despite HN2’s potency
during a shorter 12-h treatment, its measured decrease in cytotoxicity after 24-h of treatment and
lower levels of apoptotic response may be largely due to its short half-life.
On the contrary, DEB and ECH, each with half-lives longer than the 24-h treatment
length, showed greater cross-linking potentials than HN2. Their ability to form cross-links also
correlated with their apoptotic potential. DEB was able to induce highly significant levels of
apoptosis after 24-h treatment (p < 0.00001) and for 12-h of treatment using the higher dose (p <
0.0005). Similarly, ECH was able to induce apoptosis at the 24-h LD50 concentration during 12and 24-h treatments (0.175 mM; p < 0.05 and p < 0.01). While the concentration of ECH at the
assaying time, compared to the initial concentration, was greater than that of DEB for both time
points, the ability for DEB to induce cell death and apoptosis were greater. This, and the
reactivity of DEB over ECH, may explain why the longer half-life of ECH did not correlate with
its ability to form more cross-links than DEB.
HN2 had the lowest cross-linking potential at equimolar concentrations, despite inducing
nearly as strong a cytotoxic response as DEB after 24-h of exposure. After 24-h, cells treated
with HN2 did not contain significant levels of cross-linking. HN2 was still able to elicit a

!

#$!

significant apoptotic signal during the 24-h treatment with the 24-h LD50 (p < 0.005), though
whether this is biologically relevant is unclear.
While preliminary work has been done to understand the cross-linking potential of these
compounds at 24-h under equimolar concentrations, future studies should investigate the crosslinking potential at LD50 concentrations and use methods to directly quantitate cell death.
Additionally, studies should also characterize the half-lives of these compounds in cell media to
better understand how well they are able to affect cells during treatment.
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